- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01831973
A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients
An Open-Label, Single-Arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Patients With Advanced/Metastatic Renal Cell Carcinoma
INVESTIGATIONAL PRODUCT:
TLC388 (Lipotecan*) *Lipotecan is a drug product of TLC388 HCl.
PHASE OF DEVELOPMENT:
Phase II
No. OF PATIENTS:
Approximately 40 (Stage I: 15 evaluable patients, Stage II: 25 evaluable patients)
STUDY OBJECTIVES:
Primary
• To evaluate non-progression disease (non-PD) rate at the end of cycle 6
Secondary
- To evaluate progression free survival (PFS)
- To evaluate overall survival (OS)
- To evaluate the duration of non-PD
- To evaluate objective response rate (ORR; where ORR= CR+PR) and duration
- To evaluate the safety profile of TLC388
- To evaluate change in health-related quality of life (HRQOL) at the end of cycle 6
STUDY DESIGN:
This is a Phase II, open-label, single-arm, multi-centre study to evaluate TLC388 monotherapy in patients with locally advanced and/or metastatic renal cell carcinoma (RCC).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A Phase II, open-label, single-arm, multi-center study to evaluate TLC388 monotherapy in patients with locally advanced and/or metastatic RCC. The study consisted of a Screening/Baseline Period, a Treatment Period and a post-treatment Follow-Up Period for PFS and OS.
Patients were to be recruited at two stages. Stage I recruited 15 evaluable patients, who had completed at least 2 cycles of treatment with one tumor assessment. If ≤ 5 patients did not develop PD at the end of cycle 6 per RECIST, no patients were to be recruited for Stage II and the study was to be closed. If > 5 patients did not develop PD at the end of cycle 6, a total of 40 evaluable patients (additional 25 evaluable patients for Stage II) were to be recruited thereafter.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Kaohsiung, Taiwan, 833
- Chang Gung Memorial Hospital. Kaohsiung Branch
-
Taichung, Taiwan, 404
- China Medical University Hospital
-
Taichung, Taiwan, 407
- Taichung Veterans General Hospital
-
Taipei, Taiwan, 10002
- National Taiwan University Hospital
-
Taoyuan, Taiwan, 333
- Chang Gung Memorial Hospital: LinKou Branch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
- Adult patients defined by age ≥ 18 years
- Histologically confirmed Renal cell carcinoma (RCC)
- Locally advanced or metastatic RCC. Locally advanced RCC: defined as a stage T3/T4 disease, not amenable to curative surgery or radiation therapy, with involvement of renal vein/vena cava/peripelvic and perirenal fat/adrenal gland, or invasion beyond Gerota's fascia. Metastatic RCC: equivalent to Stage IV RCC, according to American Joint Committee on Cancer (AJCC) staging
- Eastern Collaborative Oncology Group (ECOG) Performance Status of ≤ 2. But for the patient with failure of ≥ 2 prior target therapies, ECOG should be ≤ 1.
- Documented RCC disease with measurable or non-measurable lesion on imaging by RECIST v1.1 (Response Evaluation Criteria in Solid Tumors) criteria
- Documented treatment failure of at least 1 prior target therapy (sorafenib, sunitinib pazopanib or other VEGF TKI, bevacizumab, temsirolimus, everolimus or other mTOR inhibitor) for advanced or metastatic RCC. If treatment-naïve, patients with poor prognosis features according to Memorial Sloan-Kettering Cancer Centre (MSKCC) risk criteria are acceptable
- Any acute or chronic adverse effects of prior therapy have resolved to <Grade 2 as determined by CTCAE v4.0 criteria
Laboratory values at screening:
- Absolute neutrophil count ≥ 1,500 /mm3;
- Platelets ≥ 100,000 /mm3;
- Hemoglobin ≥ 9.0 g/dL;
- Total bilirubin ≤ 1.5 times the upper limit of normal;
- AST (SGOT) ≤ 2.5 times the upper limit of normal;
- ALT (SGPT) ≤ 2.5 times the upper limit of normal;
- Serum creatinine ≤ 2 times the upper limit of normal;
EXCLUSION CRITERIA:
- Pregnancy or lactation. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrolment. Male and female patients of childbearing potential must agree to use appropriate birth control (barrier methods with spermicides, oral or parenteral contraceptives and/or intrauterine devices) during the entire duration of the study, or the patient must be surgically sterile (with documentation in the patient's medical records)
- Receipt of any chemotherapy for RCC
- Had cardiac angioplasty or stenting event, myocardial infarction or unstable angina within 3 months of study entry
- Persistent QTc >450 ms for males, or >470 ms for females, according to Fridericia's correction
- Patients with Grade 3 or greater hyponatremia at screening
- History of Class III or IV congestive heart failure according to New York Heart Association (NYHA) classification
- History of another malignancy, except for non-basal-cell carcinoma of skin or carcinoma-in-situ of the uterine cervix, and not disease free ≥5 years
- History or presence of central nervous system (CNS) metastasis or leptomeningeal tumors as documented by CT or MRI scan, analysis of cerebrospinal fluid or neurological exam
- History of human immunodeficiency virus infection
- Presence of active, uncontrolled infection
- Radiotherapy received within 4 weeks prior to baseline
- Use of any investigational agents within 4 weeks of baseline
- Major surgery within 4 weeks prior to baseline
- Receipt of radiotherapy to >25 % of bone marrow
- Concomitant treatment with, or anticipated use of, pharmaceutical or herbal agents which are potent inhibitors or inducers of cytochrome P450 enzymes (Appendix D1), unless approved by the Sponsor
- Uncontrolled intercurrent illness that would jeopardize patient safety, or interfere with the objectives of the protocol, or limit patient compliance with study requirements, as determined by the Investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lipotecan, injection for chemotherapy
Patients receive TLC388 (50 mg/m2) given as a 30-minute IV infusion, on Days 1, 8, and 15 of a 28-day cycle.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Non-progression disease (non-PD) rate at the end of cycle 6
Time Frame: 6 months
|
Non-progression disease rate after cycle 6
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS)
Time Frame: 3 years
|
Progression free survival
|
3 years
|
Overall survival (OS)
Time Frame: 3 years
|
Overall sruvival
|
3 years
|
Duration of non-PD
Time Frame: 3 years
|
Non-progression disease rate (overall)
|
3 years
|
Objective response rate (ORR; where ORR= CR+PR) and duration
Time Frame: 3 years
|
Objective response rate and duration
|
3 years
|
Safety profile of TLC388
Time Frame: 3 years
|
Serious/ Adverse Events
|
3 years
|
Change in health-related quality of life (HRQOL) at the end of cycle 6
Time Frame: 6 months
|
Quality of life after cycle 6
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Dr. Yvonne Shi, Taiwan Liposome Company
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TLC388.3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced/Metastasis Renal Cell Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Advanced Sarcomatoid Renal Cell CarcinomaUnited States
-
Korean Urological Oncology SocietyPfizerUnknownClear Cell Renal Cell Carcinoma | MetastasisKorea, Republic of
-
National Cancer Institute (NCI)Active, not recruitingClear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Locally Advanced Malignant Solid Neoplasm | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Locally Advanced Clear Cell Renal Cell CarcinomaUnited States
-
Mabwell (Shanghai) Bioscience Co., Ltd.Not yet recruitingAdvanced Clear Cell Renal Cell Carcinoma
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
ExelixisArcus Biosciences, Inc.RecruitingAdvanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid TumorsUnited States
-
Calithera Biosciences, IncCompletedMetastatic Renal Cell Carcinoma | Advanced Renal Cell CarcinomaUnited States, United Kingdom, Australia, France, Italy, Germany, Spain, New Zealand
-
Argos TherapeuticsTerminatedRenal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Advanced Renal Cell CarcinomaIsrael, Spain, United States, Czechia, Canada, Italy, Hungary, United Kingdom
Clinical Trials on Lipotecan
-
Taiwan Liposome CompanyTerminatedHepatocellular CarcinomaChina, Taiwan
-
Taiwan Liposome CompanyCompletedAdvanced Solid TumorsTaiwan, United States
-
Taiwan Liposome CompanyTerminatedHepatoCellular Carcinoma | Portal Vein Tumor ThrombosisTaiwan
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Chang Gung Memorial Hospital; Kaohsiung... and other collaboratorsCompletedNeuroendocrine CarcinomasTaiwan
-
Taiwan Liposome CompanyTerminatedA Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular CarcinomaCarcinoma, HepatocellularTaiwan